Polyrizon Ltd. (PLRZ), Monday announced positive results from a new in-vitro pre-clinical study, evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose.
The study found that PL-14 significantly reduced allergen transfer at all time points compared with HPMC, suggesting that PL-14 can form an effective intranasal hydrogel barrier capable of reducing allergen exposure to nasal tissue.
In light of these results, the company plans to continue to advance its preclinical development program, and support future clinical studies aimed at establishing PL-14's regulatory pathway and real-world clinical benefit for allergy prevention.
Currently, PLRZ is moving up 5.65 percent, to $13.47 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.